002424 贵州百灵
已收盘 12-12 15:00:00
资讯
新帖
简况
从“纾困共赢”到“对簿公堂”：贵州百灵与华创证券纠葛背后的多重风险
新浪证券 · 12-12 16:22
从“纾困共赢”到“对簿公堂”：贵州百灵与华创证券纠葛背后的多重风险
贵州百灵给姜伟敲响了警钟
牛刀商业评论 · 12-05
贵州百灵给姜伟敲响了警钟
贵州百灵：董事长姜伟因涉嫌违反证券法律法规等违规行为被证监会立案调查
证券之星 · 12-04
贵州百灵：董事长姜伟因涉嫌违反证券法律法规等违规行为被证监会立案调查
公司快评︱实控人涉嫌内幕交易、信披违法等被查，贵州百灵如何重塑信任？
每日经济新闻 · 12-04
公司快评︱实控人涉嫌内幕交易、信披违法等被查，贵州百灵如何重塑信任？
贵州百灵（002424）披露关于实际控制人收到中国证券监督管理委员会立案告知书的公告，12月03日股价下跌0.89%
证券之星 · 12-03
贵州百灵（002424）披露关于实际控制人收到中国证券监督管理委员会立案告知书的公告，12月03日股价下跌0.89%
贵州百灵：糖宁通络临床试验有序推进
证券之星 · 12-03
贵州百灵：糖宁通络临床试验有序推进
贵州百灵：截止2025年11月20日股东总户数为83,885
证券之星 · 12-03
贵州百灵：截止2025年11月20日股东总户数为83,885
贵州百灵集团药业实际控制人江伟因涉嫌违规被证券监管机构调查
美股速递 · 12-03
贵州百灵集团药业实际控制人江伟因涉嫌违规被证券监管机构调查
贵州百灵最新公告：因涉嫌内幕交易等实控人姜伟被证监会立案
证券之星 · 12-03
贵州百灵最新公告：因涉嫌内幕交易等实控人姜伟被证监会立案
股市必读：贵州百灵（002424）11月13日披露最新机构调研信息
证券之星 · 11-14
股市必读：贵州百灵（002424）11月13日披露最新机构调研信息
贵州百灵：糖宁通络项目将从2期临床试验开始
证券之星 · 10-30
贵州百灵：糖宁通络项目将从2期临床试验开始
贵州百灵：截止2025年10月20日股东总户数为96,305
证券之星 · 10-30
贵州百灵：截止2025年10月20日股东总户数为96,305
股市必读：贵州百灵(002424)股东户数8.36万户，较上期减少2.67%
证券之星 · 10-27
股市必读：贵州百灵(002424)股东户数8.36万户，较上期减少2.67%
贵州百灵（002424）2025年三季报简析：净利润同比下降35.6%
证券之星 · 10-26
贵州百灵（002424）2025年三季报简析：净利润同比下降35.6%
贵州百灵(002424)10月10日股东户数8.36万户，较上期减少2.67%
证券之星 · 10-25
贵州百灵(002424)10月10日股东户数8.36万户，较上期减少2.67%
贵州百灵(002424.SZ)：第三季度净利润同比上升559.90%
中金财经 · 10-24
贵州百灵(002424.SZ)：第三季度净利润同比上升559.90%
贵州百灵：截止2025年9月30日股东总户数为83,672
证券之星 · 10-16
贵州百灵：截止2025年9月30日股东总户数为83,672
异动快报：贵州百灵（002424）10月16日9点41分触及涨停板
证券之星 · 10-16
异动快报：贵州百灵（002424）10月16日9点41分触及涨停板
贵州百灵(002424.SZ)：糖宁通络片临床试验申请获批准
智通财经 · 10-15
贵州百灵(002424.SZ)：糖宁通络片临床试验申请获批准
贵州百灵：截止2025年10月10日股东总户数为83,607
证券之星 · 10-13
贵州百灵：截止2025年10月10日股东总户数为83,607
暂无数据
公司概况
公司名称：
贵州百灵企业集团制药股份有限公司
所属行业：
医药制造业
上市日期：
2010-06-03
主营业务：
贵州百灵企业集团制药股份有限公司的主营业务是苗药研发、生产、销售。公司的主要产品是中成药、中药材、西药、医疗服务。公司已获得国家认定企业技术中心、全国创新型企业、国家火炬计划重点高新技术企业、国家级技术创新示范企业、国家知识产权示范企业、贵州省创新型领军示范企业、贵州省知识产权优势企业等荣誉。
发行价格：
40.00
{"stockData":{"symbol":"002424","market":"SZ","secType":"STK","nameCN":"贵州百灵","latestPrice":5.35,"timestamp":1765523037000,"preClose":5.42,"halted":0,"volume":12742800,"delay":0,"changeRate":-0.0129,"floatShares":1213000000,"shares":1398000000,"eps":0.0016,"marketStatus":"已收盘","change":-0.07,"latestTime":"12-12 15:00:00","open":5.4,"high":5.42,"low":5.33,"amount":68505300,"amplitude":0.0166,"askPrice":5.35,"askSize":95,"bidPrice":5.34,"bidSize":130,"shortable":0,"etf":0,"ttmEps":0.0016,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765762200000},"marketStatusCode":5,"adr":0,"adjPreClose":5.42,"symbolType":"stock","openAndCloseTimeList":[[1765503000000,1765510200000],[1765515600000,1765522800000]],"highLimit":5.96,"lowLimit":4.88,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1397598400,"isCdr":false,"pbRate":2.32,"roa":"--","peRate":3343.75,"roe":"1.77%","epsLYR":0.02,"committee":-0.052656,"marketValue":7477000000,"turnoverRate":0.0105,"status":1,"floatMarketCap":6491000000},"requestUrl":"/m/hq/s/002424/tweets","defaultTab":"tweets","newsList":[{"id":"2590298579","title":"从“纾困共赢”到“对簿公堂”：贵州百灵与华创证券纠葛背后的多重风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2590298579","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590298579?lang=zh_cn&edition=full","pubTime":"2025-12-12 16:22","pubTimestamp":1765527720,"startTime":"0","endTime":"0","summary":" 近日，贵州百灵（维权）实控人姜伟与纾困方华创证券之间的诉讼纠纷持续发酵，引发市场广泛关注。这场始于2019年的“纾困合作”，在几年间从“资本佳话”演变为对簿公堂，不仅暴露了双方在股权、财务与控制权上的多重矛盾，也为当前A股市场中频繁出现的股权变更与纾困模式敲响了警钟。姜伟方指控华创证券“以帮扶之名行控制之实”，严重干扰公司正常经营决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2025-12-12/doc-inhaprxi5673040.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["161027","BK0188","002424","BK0239","BK0077","BK0028","BK0146","BK0183"],"gpt_icon":0},{"id":"2589487892","title":"贵州百灵给姜伟敲响了警钟","url":"https://stock-news.laohu8.com/highlight/detail?id=2589487892","media":"牛刀商业评论","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589487892?lang=zh_cn&edition=full","pubTime":"2025-12-05 19:51","pubTimestamp":1764935460,"startTime":"0","endTime":"0","summary":"03行业警示贵州百灵的案例，为民营上市公司与纾困机构都敲响了警钟。贵州百灵作为 “苗药第一股”，本应在民族医药领域深耕研发、拓展市场，但姜伟却将过多精力投入跨界资本运作，导致主业逐渐失去竞争力。目前，贵州百灵与华创证券的诉讼仍在进行中，姜伟的立案调查也尚无定论，但这场 18 亿纾困罗生门带来的思考远未结束。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-12-05/doc-infzuery7585329.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0146","BK0028","002424","BK0188","BK0077","BK0239","BK0183"],"gpt_icon":0},{"id":"2588971885","title":"贵州百灵：董事长姜伟因涉嫌违反证券法律法规等违规行为被证监会立案调查","url":"https://stock-news.laohu8.com/highlight/detail?id=2588971885","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588971885?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:00","pubTimestamp":1764846055,"startTime":"0","endTime":"0","summary":"证券之星消息，12月4日贵州百灵公开信息显示，董事长姜伟因涉嫌违反证券法律法规,违规交易,信息披露违规被中国证券监督管理委员会立案调查。详细违规行为如下：因涉嫌内幕交易、信息披露违法、违反限制性规定转让股票处罚决定如下：立案以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400032273.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002424","BK0188","BK0146","BK0028","161027","BK0183","BK0239","BK0077"],"gpt_icon":0},{"id":"2588700840","title":"公司快评︱实控人涉嫌内幕交易、信披违法等被查，贵州百灵如何重塑信任？","url":"https://stock-news.laohu8.com/highlight/detail?id=2588700840","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588700840?lang=zh_cn&edition=full","pubTime":"2025-12-04 13:13","pubTimestamp":1764825180,"startTime":"0","endTime":"0","summary":" 12月3日晚，贵州百灵（维权）发布公告称，公司实控人姜伟因涉嫌内幕交易、信息披露违法及违反限制性规定转让股票被中国证监会立案调查。这一消息犹如平地惊雷，再次将贵州百灵推至风口浪尖，而此前公司因财务报表真实性存疑等问题已备受市场关注，如今实控人被查，无疑是雪上加霜。 总之，贵州百灵目前面临着实控人被查和财务疑云的双重压力。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-12-04/doc-infzrepk8739286.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-12-04/doc-infzrepk8739286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0146","BK0188","BK0239","BK0183","002424","BK0077","BK0028"],"gpt_icon":0},{"id":"2588042557","title":"贵州百灵（002424）披露关于实际控制人收到中国证券监督管理委员会立案告知书的公告，12月03日股价下跌0.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588042557","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588042557?lang=zh_cn&edition=full","pubTime":"2025-12-03 22:22","pubTimestamp":1764771740,"startTime":"0","endTime":"0","summary":"截至2025年12月3日收盘，贵州百灵报收于5.57元，较前一交易日下跌0.89%，最新总市值为77.85亿元。公司近日发布公告称，实际控制人姜伟先生收到中国证券监督管理委员会下发的《立案告知书》，因涉嫌内幕交易、信息披露违法、违反限制性规定转让股票，中国证监会决定对其立案。本次立案仅涉及姜伟先生个人，与公司日常经营管理无关，不会对公司及子公司生产经营活动产生影响。姜伟先生将配合调查，公司将持续关注相关进展并履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300040367.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0239","BK0146","002424","BK0077","BK0188","BK0028"],"gpt_icon":0},{"id":"2588011046","title":"贵州百灵：糖宁通络临床试验有序推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2588011046","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588011046?lang=zh_cn&edition=full","pubTime":"2025-12-03 20:54","pubTimestamp":1764766483,"startTime":"0","endTime":"0","summary":"证券之星消息，贵州百灵(002424)12月03日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，糖宁通络适应症糖尿病二期视网膜病变三期临床有一年了，问一下临床患者入组现在是什么情况，谢谢贵州百灵回复：感谢您对公司的关注。公司糖宁通络项目临床实验正在按照试验计划有序推进，研发项目取得阶段性进展后，公司将会及时的履行信披义务。谢谢，以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300037347.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0077","BK0146","BK0239","BK0188","002424","BK0183"],"gpt_icon":0},{"id":"2588046758","title":"贵州百灵：截止2025年11月20日股东总户数为83,885","url":"https://stock-news.laohu8.com/highlight/detail?id=2588046758","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588046758?lang=zh_cn&edition=full","pubTime":"2025-12-03 20:54","pubTimestamp":1764766482,"startTime":"0","endTime":"0","summary":"证券之星消息，贵州百灵(002424)12月03日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，请问截止到11月20日的最新股东人数是多少，谢谢！贵州百灵回复：感谢您对公司的关注，截止2025年11月20日，公司股东总户数为83,885。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300037346.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0146","002424","BK0077","BK0239","BK0183","BK0028"],"gpt_icon":0},{"id":"1163469702","title":"贵州百灵集团药业实际控制人江伟因涉嫌违规被证券监管机构调查","url":"https://stock-news.laohu8.com/highlight/detail?id=1163469702","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163469702?lang=zh_cn&edition=full","pubTime":"2025-12-03 17:29","pubTimestamp":1764754149,"startTime":"0","endTime":"0","summary":"贵州百灵集团药业实际控制人江伟因涉嫌违规被证券监管机构调查。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","002424","BK0146","BK0183","BK0239","BK0077","BK0028"],"gpt_icon":0},{"id":"2588501457","title":"贵州百灵最新公告：因涉嫌内幕交易等实控人姜伟被证监会立案","url":"https://stock-news.laohu8.com/highlight/detail?id=2588501457","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588501457?lang=zh_cn&edition=full","pubTime":"2025-12-03 17:21","pubTimestamp":1764753680,"startTime":"0","endTime":"0","summary":"贵州百灵(002424.SZ)公告称，公司实际控制人姜伟近日收到中国证监会立案告知书，因涉嫌内幕交易、信息披露违法、违反限制性规定转让股票，中国证监会决定对其进行立案。本次立案系对姜伟个人的调查，与公司日常经营无关，不会影响上市公司及子公司生产经营。姜伟将配合证监会的调查工作，公司将持续关注进展并及时履行信息披露义务。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300026758.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002424","BK0183","BK0146","BK0188","BK0077","BK0028","BK0239"],"gpt_icon":0},{"id":"2583130595","title":"股市必读：贵州百灵（002424）11月13日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2583130595","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583130595?lang=zh_cn&edition=full","pubTime":"2025-11-14 02:40","pubTimestamp":1763059227,"startTime":"0","endTime":"0","summary":"截至2025年11月13日收盘，贵州百灵报收于6.1元，上涨0.16%，换手率3.24%，成交量39.35万手，成交额2.37亿元。当日关注点来自交易信息汇总：11月13日主力资金净流出1114.82万元，散户资金净流入1812.58万元。来自机构调研要点：黄连解毒丸已完成Ⅲ期临床研究，正准备上市前沟通，有望实现我国“证候类”中药新药零的突破。公司已对糖宁通络项目开展知识产权保护，并持续加强相关措施。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400000967.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0077","BK0146","BK0239","BK0188","002424","BK0183"],"gpt_icon":0},{"id":"2579164144","title":"贵州百灵：糖宁通络项目将从2期临床试验开始","url":"https://stock-news.laohu8.com/highlight/detail?id=2579164144","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579164144?lang=zh_cn&edition=full","pubTime":"2025-10-30 20:48","pubTimestamp":1761828501,"startTime":"0","endTime":"0","summary":"证券之星消息，贵州百灵(002424)10月30日在投资者关系平台上答复投资者关心的问题。投资者提问：请问尊敬的董秘这次糖宁通络片开展用于2型糖尿病的临床试验，也是豁免Ⅰ、Ⅱ期临床试验直接进入Ⅲ期临床吗？贵州百灵回复：感谢您对公司的关注。公司糖宁通络项目本次收到的关于用于 2 型糖尿病（湿热蕴结证）适应症的《药物临床试验批准通知书》，相关研究工作将从2期临床试验开始。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000041533.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","002424","BK0188","BK0183","BK0146","BK0028"],"gpt_icon":0},{"id":"2579144969","title":"贵州百灵：截止2025年10月20日股东总户数为96,305","url":"https://stock-news.laohu8.com/highlight/detail?id=2579144969","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579144969?lang=zh_cn&edition=full","pubTime":"2025-10-30 20:48","pubTimestamp":1761828500,"startTime":"0","endTime":"0","summary":"证券之星消息，贵州百灵(002424)10月30日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，请问10月20日股东人数是多少人，谢谢贵州百灵回复：感谢您对公司的关注，截止2025年10月20日，公司股东总户数为96,305。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000041532.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0146","BK0183","BK0239","BK0028","002424","BK0077","BK0188"],"gpt_icon":0},{"id":"2578869652","title":"股市必读：贵州百灵(002424)股东户数8.36万户，较上期减少2.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578869652","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578869652?lang=zh_cn&edition=full","pubTime":"2025-10-27 03:52","pubTimestamp":1761508330,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，贵州百灵报收于5.83元，下跌1.19%，换手率2.41%，成交量29.25万手，成交额1.72亿元。当日关注点来自交易信息汇总：10月24日主力资金净流出835.03万元，散户资金净流入754.58万元。股本股东变化股东户数变动截至2025年10月10日，贵州百灵股东户数为8.36万户，较9月30日减少2291.0户，减幅2.67%；户均持股数量由1.63万股上升至1.67万股，户均持股市值为8.89万元。表决结果为同意5票，反对0票，弃权0票，议案获全票通过。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700000985.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002424","BK0239","BK0028","BK0077","BK0188","BK0183","BK0146"],"gpt_icon":0},{"id":"2578668315","title":"贵州百灵（002424）2025年三季报简析：净利润同比下降35.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578668315","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578668315?lang=zh_cn&edition=full","pubTime":"2025-10-26 06:12","pubTimestamp":1761430350,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期贵州百灵发布2025年三季报。根据财报显示，贵州百灵净利润同比下降35.6%。截至本报告期末，公司营业总收入21.02亿元，同比下降24.28%，归母净利润5681.44万元，同比下降35.6%。按单季度数据看，第三季度营业总收入6.4亿元，同比上升1.11%，第三季度归母净利润497.98万元，同比上升559.9%。去年的净利率为0.96%，算上全部成本后，公司产品或服务的附加值不高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600001991.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002424"],"gpt_icon":0},{"id":"2578574601","title":"贵州百灵(002424)10月10日股东户数8.36万户，较上期减少2.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578574601","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578574601?lang=zh_cn&edition=full","pubTime":"2025-10-25 17:23","pubTimestamp":1761384202,"startTime":"0","endTime":"0","summary":"证券之星消息，近日贵州百灵披露，截至2025年10月10日公司股东户数为8.36万户，较9月30日减少2291.0户，减幅为2.67%。在中药行业个股中，贵州百灵股东户数高于行业平均水平，截至10月10日，中药行业平均股东户数为5.39万户。从股价来看，2025年9月30日至2025年10月10日，贵州百灵区间涨幅为1.33%，在此期间股东户数减少2291.0户，减幅为2.67%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102500014770.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0146","BK0188","BK0077","BK0028","002424","BK0239"],"gpt_icon":0},{"id":"2577516218","title":"贵州百灵(002424.SZ)：第三季度净利润同比上升559.90%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577516218","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577516218?lang=zh_cn&edition=full","pubTime":"2025-10-24 20:27","pubTimestamp":1761308822,"startTime":"0","endTime":"0","summary":"格隆汇10月24日丨贵州百灵(002424.SZ)公布2025年第三季度报告，营业收入为6.40亿元，同比上升1.11%；归属于上市公司股东的净利润为497.98万元，同比上升559.90%；归属于上市公司股东的扣除非经常性损益的净利润为736.42万元，同比上升203.82%。\r\n\r\n \r\n\r\n 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱：news_center@staff.hexun.com","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251024/31734825.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["002424"],"gpt_icon":0},{"id":"2575698749","title":"贵州百灵：截止2025年9月30日股东总户数为83,672","url":"https://stock-news.laohu8.com/highlight/detail?id=2575698749","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575698749?lang=zh_cn&edition=full","pubTime":"2025-10-16 20:48","pubTimestamp":1760618898,"startTime":"0","endTime":"0","summary":"证券之星消息，贵州百灵(002424)10月16日在投资者关系平台上答复投资者关心的问题。投资者提问：问002424截止9月30日股东人数贵州百灵回复：感谢您对公司的关注，截止2025年9月30日，公司股东总户数为83,672。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101600035496.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0146","BK0188","BK0239","BK0077","BK0028","BK0183","002424"],"gpt_icon":0},{"id":"2575376461","title":"异动快报：贵州百灵（002424）10月16日9点41分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2575376461","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575376461?lang=zh_cn&edition=full","pubTime":"2025-10-16 09:45","pubTimestamp":1760579128,"startTime":"0","endTime":"0","summary":"证券之星10月16日盘中消息，9点41分贵州百灵触及涨停板。目前价格5.95，上涨9.98%。其所属行业中药目前上涨。该股为中药，医药，创新药概念热股，当日中药概念上涨0.26%，医药概念上涨0.15%，创新药概念上涨0.07%。10月15日的资金流向数据方面，主力资金净流出183.03万元，占总成交额1.65%，游资资金净流入6.75万元，占总成交额0.06%，散户资金净流入176.28万元，占总成交额1.59%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101600008404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002424","BK0188","BK0146","BK0028","BK0183","BK0239","BK0077"],"gpt_icon":0},{"id":"2575123207","title":"贵州百灵(002424.SZ)：糖宁通络片临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2575123207","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575123207?lang=zh_cn&edition=full","pubTime":"2025-10-15 17:33","pubTimestamp":1760520799,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贵州百灵(002424.SZ)公告，公司全资子公司百灵毓秀(珠海)医药有限公司(简称“百灵毓秀”)收到国家药品监督管理局(NMPA)核准签发的《药物临床试验批准通知书》，由百灵毓秀申报的糖宁通络片临床试验申请获得批准，同意本品开展用于2型糖尿病的临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1355393.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"贵州百灵(002424.SZ)：糖宁通络片临床试验申请获批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","002424","BK0146","BK0028","BK0239","BK0077","BK0188"],"gpt_icon":0},{"id":"2575640994","title":"贵州百灵：截止2025年10月10日股东总户数为83,607","url":"https://stock-news.laohu8.com/highlight/detail?id=2575640994","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575640994?lang=zh_cn&edition=full","pubTime":"2025-10-13 20:48","pubTimestamp":1760359710,"startTime":"0","endTime":"0","summary":"证券之星消息，贵州百灵(002424)10月13日在投资者关系平台上答复投资者关心的问题。投资者提问：请问到10月10日的股东人数是多少？谢谢贵州百灵回复：感谢您对公司的关注，截止2025年10月10日，公司股东总户数为83,607。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101300023438.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","002424","BK0239","BK0028","BK0146","BK0183","BK0188"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765744841720,"stockEarnings":[{"period":"1week","weight":-0.0325},{"period":"1month","weight":-0.1215},{"period":"3month","weight":-0.0978},{"period":"6month","weight":0.283},{"period":"1year","weight":0.3049},{"period":"ytd","weight":0.3896}],"compareEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0277},{"period":"3month","weight":0.0048},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1236},{"period":"ytd","weight":0.1604}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"贵州百灵企业集团制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"83885人(较上一季度减少2.28%)","perCapita":"14462股","listingDate":"2010-06-03","address":"贵州省安顺市西秀区经济技术开发区西航路212号","registeredCapital":"139759万元","survey":" 贵州百灵企业集团制药股份有限公司的主营业务是苗药研发、生产、销售。公司的主要产品是中成药、中药材、西药、医疗服务。公司已获得国家认定企业技术中心、全国创新型企业、国家火炬计划重点高新技术企业、国家级技术创新示范企业、国家知识产权示范企业、贵州省创新型领军示范企业、贵州省知识产权优势企业等荣誉。","listedPrice":40},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"贵州百灵(002424)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供贵州百灵(002424)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"贵州百灵,002424,贵州百灵股票,贵州百灵股票老虎,贵州百灵股票老虎国际,贵州百灵行情,贵州百灵股票行情,贵州百灵股价,贵州百灵股市,贵州百灵股票价格,贵州百灵股票交易,贵州百灵股票购买,贵州百灵股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"贵州百灵(002424)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供贵州百灵(002424)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}